Psyrreal VR Psychedelic Replication Feasibility Study — Estonia 2021
TBD
Detailed Description
TBD
Study Arms & Interventions
Control VR
placeboA 5-minute demonstrative VR experience in a small room with a balcony view onto a mountain range, used as a control condition for comparisons with EDI, PIQ, and MEQ30 measures.
Interventions
- Placebo• single dose• 1 doses total
5-minute demonstrative VR experience
Psyrreal VR
experimentalA 45-minute psychedelic-inspired virtual reality experience implementing various audiovisual and narrative phenomenological elements.
Interventions
- Placebo• single dose• 1 doses total
45-minute VR experience implemented on the second day of a 2-day intervention
Primary Results(1 publication)
Participants
Response Rates
≥50% decrease from baseline in EST-Q2 Depression score
EST-Q2 Depression score <12 (remission)
Adverse Events (from all publications)
| Arm / Group | n | Any TEAE | Severe | Serious | Discont. |
|---|---|---|---|---|---|
| Control VRplacebo | — | — | — | — | — |
| Psyrreal VRexperimental | 13 | 4(30.8%) | 0(0.0%) | 0(0.0%) | 0(0.0%) |
* Safety data is reported for the entire study population (N=13) across both VR experiences (Control VR and Psyrreal VR) and is not disaggregated by individual VR experience. Therefore, specific counts for the Control VR arm are not available.
* Safety data is reported for the entire study population (N=13) across both VR experiences (Control VR and Psyrreal VR). Four participants (out of 13) mentioned transient nausea. No severe or serious adverse effects were reported, and no discontinuations due to adverse events occurred. This pooled data is assigned to the experimental arm (arm2) as per instructions for pooled data.